Press Release

Ocular Hypertension Treatment Market to Grow with a CAGR of 3.82% through 2028

Rising advancements in treatment modalities are expected to drive the Global Ocular Hypertension Treatment Market growth in the forecast period, 2024-2028.

 

 According to TechSci Research report, “Ocular Hypertension Treatment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Ocular Hypertension Treatment Market stood at USD 3.67 billion in 2022 and is anticipated to grow with a CAGR of 3.82% in the forecast period, 2024-2028. The Global Ocular Hypertension Treatment Market is experiencing remarkable growth, driven by a confluence of factors that are reshaping the landscape of ocular healthcare. Ocular hypertension, characterized by elevated intraocular pressure, poses a significant risk factor for glaucoma, a leading cause of irreversible blindness worldwide. One of the primary drivers behind the growth of the ocular hypertension treatment market is the aging global population. As individuals age, the risk of developing ocular hypertension and subsequent glaucoma increases. The elderly are particularly vulnerable to these conditions due to changes in the eye's drainage system, which can impede the flow of aqueous humor and lead to elevated intraocular pressure. Changing lifestyle patterns and the prevalence of digital devices are contributing significantly to the rise in ocular hypertension cases. Prolonged screen time, extensive use of smartphones and computers, and increased exposure to artificial lighting can strain the eyes, potentially leading to ocular hypertension. As individuals of all ages spend more time engaged with screens, the demand for ocular hypertension treatments, including eye drops and preventive measures, has surged. Lifestyle factors are thus acting as a driving force behind the market's expansion.

The ocular hypertension treatment market has witnessed a notable transformation with the introduction of innovative therapeutic options. While eye drops and oral medications have traditionally been the mainstay of treatment, advancements in surgical techniques have expanded the treatment landscape. Micro-invasive glaucoma surgery (MIGS) is a prime example of this evolution. MIGS procedures are less invasive than traditional glaucoma surgeries and offer a more effective approach to managing intraocular pressure. These minimally invasive techniques have gained popularity among both patients and clinicians, enhancing the market's growth prospects.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Ocular Hypertension Treatment Market.”

 

Rising awareness about the importance of early detection and treatment of ocular hypertension is a pivotal driver behind market growth. Ophthalmologists, patient advocacy groups, and healthcare organizations are actively involved in educational campaigns to highlight the risks associated with untreated ocular hypertension. Early diagnosis and intervention not only prevent vision loss but also reduce the economic burden of treating advanced glaucoma. As more people become aware of the potential consequences of ocular hypertension, they are seeking timely treatment and contributing to market expansion.

The Global Ocular Hypertension Treatment Market is segmented into Type, Route of Administration, Distribution Channel, Regional Distribution, And Company.

Based on the Type, the Glaucoma emerged as the dominant segment in the global market for Global Ocular Hypertension Treatment Market in 2022. Intraocular hypertension refers to elevated intraocular pressure, which is a significant risk factor for the development of glaucoma. Not everyone with ocular hypertension will develop glaucoma, but a substantial proportion of glaucoma cases stem from untreated or inadequately managed intraocular hypertension. Therefore, the demand for ocular hypertension treatment is intrinsically linked to the prevention and management of glaucoma, making glaucoma the primary driver of demand within the market. Glaucoma is a leading cause of irreversible blindness globally, and it affects a substantial number of individuals. According to the World Health Organization (WHO), approximately 3% of the world's population aged 40 to 80 years has some form of glaucoma. This high prevalence of glaucoma contributes significantly to the demand for ocular hypertension treatments, as a considerable portion of those affected by glaucoma initially presented with intraocular hypertension.

Early detection and treatment of intraocular hypertension are critical in preventing the progression to glaucoma and preserving vision. As awareness of the link between intraocular hypertension and glaucoma grows, more individuals seek timely intervention to manage their elevated intraocular pressure effectively. This emphasis on early detection and treatment underscores the demand for ocular hypertension treatments, especially in cases where glaucoma can be prevented or delayed.

Based on the Distribution Channel, the Retail Pharmacy segment emerged as the dominant player in the global market for Global Ocular Hypertension Treatment Market in 2022. Retail pharmacies are widespread and easily accessible, offering a physical presence in local communities and healthcare facilities. Patients with ocular hypertension can visit these pharmacies conveniently to purchase prescribed eye drops or medications, making it a preferred choice for many individuals, especially older patients who may be less familiar with online options. Retail pharmacies provide the opportunity for patients to consult with pharmacists, who can offer guidance and answer questions about ocular hypertension medications.

Patients can receive personalized advice on proper usage, potential side effects, and interactions with other medications, which enhances treatment adherence and safety. Retail pharmacies offer immediate access to medications, allowing patients to begin treatment promptly after receiving their prescriptions. This quick turnaround is crucial in managing conditions like ocular hypertension, where timely treatment can prevent progression to glaucoma and vision loss.

North America emerged as the dominant player in the global Ocular Hypertension Treatment Market in 2022, holding the largest market share. North America boasts a highly developed and advanced healthcare infrastructure, comprising state-of-the-art medical facilities, well-trained healthcare professionals, and cutting-edge diagnostic and treatment technologies. This infrastructure supports the early diagnosis and effective management of ocular hypertension, contributing to the region's dominant position in the market. North America has a significant prevalence of ocular hypertension and glaucoma cases, partly due to an aging population. The demographic shift toward an older population is contributing to a larger patient pool in need of ocular hypertension treatments, thereby driving market growth. The region places a strong emphasis on healthcare awareness and screening programs. Increased public awareness of ocular health, regular eye check-ups, and the link between ocular hypertension and glaucoma have led to early detection and treatment, further consolidating North America's dominant market position.

 

Major companies operating in Global Ocular Hypertension Treatment Market are:

  • Angelini Spa
  • Laboratorios Sophia
  • Neurim Pharmaceuticals Ltd
  • Nicox SA
  • Novartis AG.
  • Aerie Pharmaceuticals, Inc.
  • Abbvie, Inc
  • Angelini Pharma S.p.a.
  • Chong Kun Dang pharmaceutical Corp
  • Lee Pharma Ltd

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

 “The Global Ocular Hypertension Treatment Market is poised for substantial growth in the coming years. This optimism is fueled by a convergence of factors that are reshaping the landscape of ocular healthcare. Rising awareness about ocular health, coupled with increased access to advanced diagnostic tools, is expected to lead to early detection and intervention for ocular hypertension, preventing its progression to glaucoma. Pharmaceutical innovations, including more patient-friendly eye drops and sustained-release medications, are improving treatment adherence and efficacy. Minimally invasive surgical techniques, such as Micro-Invasive Glaucoma Surgery (MIGS), are gaining prominence for their superior safety profiles and quicker recovery times. Additionally, the expansion of telemedicine and remote monitoring is enhancing accessibility to ocular care, particularly in underserved regions.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Ocular Hypertension Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Intraocular Hypertension, Glaucoma), By Route Of Administration (Oral, Parenteral, Other), By Distribution Channel (Retail Pharmacy, Online Pharmacy, Other) By Region and Competition”, has evaluated the future growth potential of Global Ocular Hypertension Treatment Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Ocular Hypertension Treatment Market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com

Relevant News